Cancer Monoclonal Antibodies Market Report: Trends, Forecast and Competitive Analysis to 2030

Cancer Monoclonal Antibodies Trends and Forecast

The future of the global cancer monoclonal antibodies market looks promising with opportunities in the hospital and research institute markets. The global cancer monoclonal antibodies market is expected to reach an estimated $153.7 billion by 2030 with a CAGR of 12.4% from 2024 to 2030. The major drivers for this market are increasing investment in research and development activities, rising inclination towards personalized medicines, and growing prevalance of cancer across the globe.

A more than 150-page report is developed to help in your business decisions.

Cancer Monoclonal Antibodies by Segment

The study includes a forecast for the global cancer monoclonal antibodies by type, application, end use, and region.

Cancer Monoclonal Antibodies Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Humanized
• Human
• Chimeric
• Murine

Cancer Monoclonal Antibodies Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Blood Cancer
• Breast Cancer
• Lung Cancer
• Melanoma
• Colorectal Cancer
• Liver Cancer
• Others

Cancer Monoclonal Antibodies Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Research Institutes
• Others

Cancer Monoclonal Antibodies Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Cancer Monoclonal Antibodies Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer monoclonal antibodies companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer monoclonal antibodies companies profiled in this report include-

• F. Hoffmann-La Roche
• Bristol Myers Squibb
• Merck
• GlaxoSmithKline
• Johnson & Johnson
• Amgen
• Novartis
• AstraZeneca
• Eli Lilly
• AbbVie

Cancer Monoclonal Antibodies Market Insights

Lucintel forecasts that humanized is expected to witness the highest growth over the forecast period due to affordability, availability, and lesser production time for mouse monoclonal antibodies.

Within this market, hospitals will remain the largest segment due increasing prevalence of cancer along with growing number of patient hospitalizations.

North America will remain the largest region over the forecast period due to growing awarness towards advanced therapies, rising prevalence of cancer, and presence of major market players in the region.

Features of the Global Cancer Monoclonal Antibodies Market

Market Size Estimates: Cancer monoclonal antibodies market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer monoclonal antibodies market size by type, application, end use, and region in terms of value ($B).

Regional Analysis: Cancer monoclonal antibodies market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, end uses, and regions for the cancer monoclonal antibodies market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer monoclonal antibodies market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the cancer monoclonal antibodies market size?

Answer: The global cancer monoclonal antibodies market is expected to reach an estimated $153.7 billion by 2030.

Q2. What is the growth forecast for cancer monoclonal antibodies market?

Answer: The global cancer monoclonal antibodies market is expected to grow with a CAGR of 12.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the cancer monoclonal antibodies market?

Answer: The major drivers for this market are increasing investment in research and development activities, rising inclination towards personalized medicines, and growing prevalance of cancer across the globe.

Q4. What are the major segments for cancer monoclonal antibodies market?

Answer: The future of the cancer monoclonal antibodies market looks promising with opportunities in the hospital and research institute markets.

Q5. Who are the key cancer monoclonal antibodies market companies?

Answer: Some of the key cancer monoclonal antibodies companies are as follows:

• F. Hoffmann-La Roche
• Bristol Myers Squibb
• Merck
• GlaxoSmithKline
• Johnson & Johnson
• Amgen
• Novartis
• AstraZeneca
• Eli Lilly
• AbbVie

Q6. Which cancer monoclonal antibodies market segment will be the largest in future?

Answer: Lucintel forecasts that humanized is expected to witness the highest growth over the forecast period due to affordability, availability, and lesser production time for mouse monoclonal antibodies.

Q7. In cancer monoclonal antibodies market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing awarness towards advanced therapies, rising prevalence of cancer, and presence of major market players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the cancer monoclonal antibodies market by type (humanized, human, chimeric, and murine), application (blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer, and others), end use (hospitals, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?